Martin Bott, our interim General Manager, is Vice-President Finance at Eli Lilly and Company, responsible for special projects.
During his 31 year career at Lilly, Martin has held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he has served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and recently led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health. Martin has lived and worked in the US, Germany, UK, and Switzerland.
He holds a Master’s Degree of International Business from the University of South Carolina and a Commercial Assistant degree from Bayer AG/Chamber of Commerce Cologne.
During his 31 year career at Lilly, Martin has held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he has served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and recently led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health. Martin has lived and worked in the US, Germany, UK, and Switzerland.
He holds a Master’s Degree of International Business from the University of South Carolina and a Commercial Assistant degree from Bayer AG/Chamber of Commerce Cologne.
Speaking In
9:30 AM - 10:00 AM (PDT)
Tuesday, October 13
Governments, the health care industry, and the media have all been sounding the alarm about the…